You will be able to get a quick price and instant permission to reuse the content in many different ways. Diplopia—seeing double—is a symptom with many potential causes, both neurological and ...

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in patients ...

Objective: This study aimed to investigate the clinical factors that predict abnormal radiographic findings in adults with acute onset binocular diplopia. Methods: Medical records of consecutive ...

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the ...

The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity will soon unveil a new ...

Viridian (VRDN) shares shot up 25% after the company reported positive results from a Phase 3 study of veligrotug in the ...

RBC Capital analyst Gregory Renza raised the firm’s price target on Viridian Therapeutics (VRDN) to $47 from $44 and keeps an Outperform rating ...

Viridian Therapeutics, Inc. has recently announced positive topline results from the phase 3 Thrive-2 clinical trial of ...